1. Home
  2. AKBA vs CNL Comparison

AKBA vs CNL Comparison

Compare AKBA & CNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • CNL
  • Stock Information
  • Founded
  • AKBA 2007
  • CNL 2018
  • Country
  • AKBA United States
  • CNL Canada
  • Employees
  • AKBA N/A
  • CNL N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • CNL
  • Sector
  • AKBA Health Care
  • CNL
  • Exchange
  • AKBA Nasdaq
  • CNL NYSE
  • Market Cap
  • AKBA 336.2M
  • CNL 273.2M
  • IPO Year
  • AKBA 2014
  • CNL N/A
  • Fundamental
  • Price
  • AKBA $1.83
  • CNL $4.10
  • Analyst Decision
  • AKBA Strong Buy
  • CNL Strong Buy
  • Analyst Count
  • AKBA 1
  • CNL 1
  • Target Price
  • AKBA $7.50
  • CNL $7.00
  • AVG Volume (30 Days)
  • AKBA 2.4M
  • CNL 13.8K
  • Earning Date
  • AKBA 11-07-2024
  • CNL 01-01-0001
  • Dividend Yield
  • AKBA N/A
  • CNL N/A
  • EPS Growth
  • AKBA N/A
  • CNL N/A
  • EPS
  • AKBA N/A
  • CNL N/A
  • Revenue
  • AKBA $169,879,000.00
  • CNL N/A
  • Revenue This Year
  • AKBA N/A
  • CNL N/A
  • Revenue Next Year
  • AKBA $30.85
  • CNL N/A
  • P/E Ratio
  • AKBA N/A
  • CNL N/A
  • Revenue Growth
  • AKBA N/A
  • CNL N/A
  • 52 Week Low
  • AKBA $0.80
  • CNL $2.43
  • 52 Week High
  • AKBA $2.48
  • CNL $4.20
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 46.55
  • CNL N/A
  • Support Level
  • AKBA $1.74
  • CNL N/A
  • Resistance Level
  • AKBA $1.90
  • CNL N/A
  • Average True Range (ATR)
  • AKBA 0.09
  • CNL 0.00
  • MACD
  • AKBA -0.03
  • CNL 0.00
  • Stochastic Oscillator
  • AKBA 20.93
  • CNL 0.00

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About CNL COLLECTIVE MINING LTD

Collective Mining Ltd is an exploration and development company focused on identifying and exploring prospective mineral projects in South America. The company currently has 100% interest in two projects located in Colombia, namely, Guayabales and San Antonio. The company is responsible for discovering, permitting, and constructing the gold mine in Colombia. The company is rapidly advancing exploration on large-scale copper-gold-molybdenum porphyry targets in the mining-friendly department of Caldas in Colombia. Drilling is underway at the Guayabales project which is strategically located contiguous to the Marmato deposit, with initial assay results ongoing.

Share on Social Networks: